BHVN — Expected Trial Completion of BHV-1300 in Graves' Disease

Expected Completion of BHV-7000 Clinical Trial

Biohaven Therapeutics Ltd. and Biohaven Pharmaceuticals, Inc. are expected to complete the clinical trial for BHV-7000, a drug aimed at assessing the long-term safety and tolerability in adults with refractory focal onset epilepsy, by January 1, 2027. The trial is currently enrolling participants, with an expected enrollment count of 660 in Phase 2. This study is crucial for understanding the therapeutic potential of BHV-7000 in this specific patient population, which may have implications for future market introductions and patient treatment options.

• www.clinicaltrials.gov/study/NCT06443463

Expected Completion of Clinical Trial for BHV-8000

Biohaven Therapeutics Ltd. anticipates the completion of its clinical trial for BHV-8000, a treatment aimed at adults diagnosed with early Parkinson's disease, by September 1, 2027. The trial, which is currently recruiting participants, aims to evaluate the drug's efficacy, safety, and tolerability, with an expected enrollment of 550 individuals. BHV-8000 is being studied in both Phase 2 and Phase 3 stages, highlighting its potential significance in addressing the needs of those affected by this neurological condition.

• www.clinicaltrials.gov/study/NCT06976268

Expected Completion of BHV-7000 Clinical Trial for Idiopathic Generalized Epilepsy

Biohaven Therapeutics Ltd. expects to complete its clinical trial for BHV-7000, a drug aimed at treating idiopathic generalized epilepsy characterized by generalized tonic-clonic seizures, on July 1, 2027. The trial, which is currently in recruiting status, involves an expected enrollment of 242 participants and includes a phased study (Phase 2 and Phase 3) to evaluate the drug's safety and efficacy. This trial may significantly impact Biohaven Pharmaceuticals' pipeline and market position depending on the outcomes as it progresses toward completion.

• www.clinicaltrials.gov/study/NCT06425159

Expected Completion of Clinical Trial for BHV-7000 in Refractory Focal Onset Epilepsy

Biohaven Pharmaceuticals is set to complete a clinical trial for BHV-7000, targeting refractory focal onset epilepsy. Scheduled for September 1, 2025, this trial marks a key step in evaluating the drug's efficacy and safety, particularly for patients who have not responded to conventional therapies. The event signifies progress in the company’s development pipeline, contributing to its strategy of addressing unmet medical needs in neurology. Financial implications remain to be evaluated as outcomes from the trial could influence future stock valuations and partnerships.